The Ukrainian pharmaceutical company Farmak intends to protect its reputation and prove the quality of its products.
At a press conference on Tuesday, Farmac Technical Director Andrei Goi expressed concern about the high incidence of adverse reactions in Moldova to the Stream insulin biosimilar. In Moldova, for 60 thousand drugs, dozens of side effects have been identified, which is an exception, since in the world the ratio for this drug is 60 side effects per 10 million, and in Ukraine - 3 cases per 60 thousand. The company said that so far has access to data regarding side effects identified in Moldova but is ready to provide all the necessary information and conduct additional, to the already conducted, joint research. A relatively greater number of side effects led to the fact that the Agency for Medicines and Medical Devices of Moldova suspended the registration of the drug "Stream", which the company "Pharmac" began to deliver in 2019 after a previously won tender. In accordance with the terms of the tender, the state was supposed to purchase 413 thousand cartridges of the drug “Stream” with a quarterly supply. The total cost of the contract is $ 1.5 million. The Farmak company supplied under the contract about 60 thousand Stream cartridges in the 1st quarter, the rest are in the warehouses of its partner in Chisinau. In the second quarter, an “insulin scandal” broke out in the country, caused by a relatively large number of side effects, which led to the withdrawal of Stream registration. According to Farmana Marketing Director Susana Halilova, as a result of the entry of the drug “Stream” into the Moldovan market, the supplier of the traditional drug “Lantus” reduced the price by 3 times (from 286 to 72 lei per package), which saved the state more than $700 thousand. She emphasized that Stream is registered under various names and has medical access in 53 countries, including Japan and the European Union. The Farmak company expressed the hope that it would be granted access to cases of side effects in Moldova, which, in its opinion, could be due to the incorrectness of its use or the transition to it from other drugs, and it would be able to protect its reputation and prove the quality products through dialogue and joint research, and not through the courts. The Farmak company is the largest Ukrainian drug manufacturer that has invested in their development and production of more than $ 240 million since 1995. More than 70 pharmaceuticals manufactured by Moldova are sold in Moldova. // 10.09.2019 - InfoMarket.